1-2 of 2
Elisabetta Leo
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

The PARP1 Inhibitor AZD5305 Impairs Ovarian Adenocarcinoma Progression and Visceral Metastases in Patient-derived Xenografts Alone and in Combination with Carboplatin

Giulia Dellavedova, Alessandra Decio, Laura Formenti, Mark R. Albertella, Joanne Wilson, Anna D. Staniszewska, Elisabetta Leo, Raffaella Giavazzi, Carmen Ghilardi, Maria Rosa Bani
Journal: Cancer Research Communications
Cancer Research Communications (2023) 3 (3): 489–500.
https://doi.org/10.1158/2767-9764.CRC-22-0423
Published: 27 March 2023
View article titled, The PARP1 Inhibitor AZD5305 Impairs Ovarian Adenocarcinoma Progression and Visceral Metastases in Patient-derived Xenografts Alone and in Combination with Carboplatin
Open the PDF for The PARP1 Inhibitor AZD5305 Impairs Ovarian Adenocarcinoma Progression and Visceral Metastases in Patient-derived Xenografts Alone and in Combination with Carboplatin in another window
Includes: Supplementary data
Journal Articles

Drug–gene Interaction Screens Coupled to Tumor Data Analyses Identify the Most Clinically Relevant Cancer Vulnerabilities Driving Sensitivity to PARP Inhibition

Kunzah Jamal, Alessandro Galbiati, Joshua Armenia, Giuditta Illuzzi, James Hall, Sabrina Bentouati, Daniel Barrell, Miika Ahdesmäki, for the Functional Genomics Centre Group, Mark J. O'Connor, Elisabetta Leo, Josep V. Forment
Journal: Cancer Research Communications
Cancer Research Communications (2022) 2 (10): 1244–1254.
https://doi.org/10.1158/2767-9764.CRC-22-0119
Published: 21 October 2022
View article titled, Drug–gene Interaction Screens Coupled to Tumor Data Analyses Identify the Most Clinically Relevant Cancer Vulnerabilities Driving Sensitivity to PARP Inhibition
Open the PDF for Drug–gene Interaction Screens Coupled to Tumor Data Analyses Identify the Most Clinically Relevant Cancer Vulnerabilities Driving Sensitivity to PARP Inhibition in another window
Includes: Supplementary data